BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 17296379)

  • 1. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
    Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
    J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach.
    Tewari A; Divine G; Chang P; Shemtov MM; Milowsky M; Nanus D; Menon M
    J Urol; 2007 Mar; 177(3):911-5. PubMed ID: 17296374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short- and long-term mortality with localized prostate cancer.
    Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
    Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
    Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
    Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y; Loblaw A; Klotz L
    J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
    J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities.
    Tewari A; Johnson CC; Divine G; Crawford ED; Gamito EJ; Demers R; Menon M
    J Urol; 2004 Apr; 171(4):1513-9. PubMed ID: 15017210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer and the Will Rogers phenomenon.
    Albertsen PC; Hanley JA; Barrows GH; Penson DF; Kowalczyk PD; Sanders MM; Fine J
    J Natl Cancer Inst; 2005 Sep; 97(17):1248-53. PubMed ID: 16145045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy).
    Tewari A; Raman JD; Chang P; Rao S; Divine G; Menon M
    Urology; 2006 Dec; 68(6):1268-74. PubMed ID: 17169648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.
    Carter CA; Donahue T; Sun L; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Jackmaan S; Moul JW
    J Clin Oncol; 2003 Nov; 21(21):4001-8. PubMed ID: 14581423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.